ClinicalTrials.gg
Active, not recruitingNCT07105254Updated Nov 20, 2026

An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)

A Phase 2 interventional study of Roflumilast topical 0.3% foam in Non-segmental Vitiligo, sponsored by Derm Texas, PLLC. Active, not recruiting at 1 site in United States. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Derm Texas, PLLC · Phase 2, Interventional, and Treatment

How we know

Updated Nov 20, 2026Now Active, not recruitingStart date moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
2 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 80 studies in Vitiligo with a site in United States — 13 open to participants now, 24 under way, 7 of them phase 3. Vitiligo · United States.

Planned enrollment
44th of 68
20 · median 37
Started
2025
with 4 others
Phase 2
31 of 80
5 open now
Primary completion
2027-07
later than 12 of 23 live
Registered
73rd of 80
by date

Among the 80 studies in Vitiligo with a site in United States, this one is the 44th largest by planned enrollment of the 68 interventional ones that give a count, is one of 5 that started in 2025, is one of 31 in phase 2, reaches primary completion later than 12 of the 23 other live ones, and was the 73rd registered.

Vitiligo

343 studies on the registry are indexed under Vitiligo; 95 are open to participants now.

Browse Vitiligo studies →

Open to participants now

13 of the 80 studies in Vitiligo with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 47 Vitiligo studies recruiting now, 13 (28%) set no upper age limit and 28 (60%) stop at 75 or younger; 17 take children under 18; 8 take healthy volunteers.

This study: 2 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Vitiligo with a site in United States, or all of them as a file.
02

Study summary

An open-label single center, proof of concept study evaluating the efficacy of Roflumilast foam 0.3% in pediatric subjects with Non-Segmental Vitiligo (NSV)

03

Conditions studied

  • Non-segmental Vitiligo

Browse trials for

04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects aged 2 years but less than 18 years
  2. Pediatric and adolescent subjects: of parent(s) or legal guardian, and, if age appropriate, assent by the subjects, as required by local laws.
  3. Diagnosis of non-segmental vitiligo based on clinical history and dermatology examination for at least 3 months.
  4. Diagnosis of non-segmental vitiligo with the following:

    1. BSA affected \< 10% AND
    2. At least 0.5% BSA affected on the face. AND
    3. Pigmented hair within some of the areas of vitiligo on the face
  5. In good health as judged by the Investigator, based on the medical history, and dermatology examination.
  6. Subjects and parent(s)/legal guardian (s) are considered reliable and capable of adhering to the Protocol and visit schedule, according to the judgment of the Investigator.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with any serious medical condition or physical examination abnormality that would prevent study participation or place the subject at significant risk, as judged by the Investigator.
  2. Subjects with known or suspected:

    1. Severe renal insufficiency
    2. Moderate to severe hepatic disorders ( B or C)
    3. Subjects who cannot discontinue prohibited medications and treatments prior to the Baseline visit and during the study, including (any biologic or experimental therapy within 12 weeks (or 5 half-lives), phototherapy within 4 weeks, immunomodulating treatments within 4 weeks, or topical treatments within 1 week.
  3. Subjects who are unwilling to refrain from using a tanning bed or other artificial light emitting devices (LEDs) for 4 weeks prior to Baseline/Day 1 and during the study.
  4. Subjects with diagnosis of other forms of vitiligo (e.g. Segmental), other differential diagnosis of vitiligo or other skin depigmentation disorders (e.g. Piedbaldism, pityriasis alba, leprosy, post-inflammatory hypopigmentation, progressive macule hypomelanosis, nevus anemicus, chemical leukoderma and tinea versicolor) that would interfere with the evaluations of the effect of the study medication, as determined by the Investigator.
  5. Subjects with known genetic dermatological conditions that overlap with non-segmental vitiligo.
  6. Known allergies to in Roflumilast foam (petrolatum, isopopyl palmitate, methylparaben, propylparaben, diethylene glycol monomethyl ether, hexylene glycol, cetylseteary alcohol, dicetyl phosphase and ceteth-10 phosphate)
  7. Subjects who cannot discontinue systemic inhibitors or dual inhibitors that inhibit both CYP3A4 and CYP1A2 simultaneously (e.g. Erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine)
  8. Subjects who have received oral roflumilast (Daxas®, Daliresp®) within 4 weeks prior to Baseline/Day 1.
  9. Females who are pregnant, wishing to become pregnant during the study, or are breast feeding.
  10. Previous treatment with Roflumilast cream or foam for vitiligo in the past 3 months.
  11. Parent (s)/legal guardians (s) who are unable to communicate, read, or understand the local language (s). Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation.
  12. Subjects who are family members of the clinical study site, clinical study staff, or sponsor, or family members of enrolled subjects living in the same house.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Open-label single center, proof of concept study evaluating the efficacy of Roflumilast foam 0.3%

    Drug: Roflumilast topical 0.3% foam

Interventions

  • DrugRoflumilast topical 0.3% foam

    Roflumilast 0.3% topical foam

06

What researchers measure

Primary outcomes

  1. The primary endpoint of this study is the number patients achieving F-VASI 50.

    The number of patients achieving a 50% improvement in their facial Vitiligo Area \& Severity Index score (F-VASI 50) at week 24.

    Time frame: Week 24

Secondary outcomes

  1. - Percentage of patients achieving: T-VASI50, T-VASI75, T-VASI90, and T-VASI100; F-VASI75, F-VASI90, and F-VASI100 at 24 weeks. Patient Assessments of - Patient Global Impression of Change-Vitiligo (PaGIC-V) - Vitiligo Noticeability Scale (VNS)

    The percentage of patients who achieve improvements of 50%, 75%, 90% and100% from baseline to week 24 in their facial and total VASI scores. (F-VASI-50, 75, 90, 100 \& T-VASI-50, 75, 90, 100). Patients will assess their impression of vitiligo change and noticeability over the course of the study.

    Time frame: Baseline, the at weeks 4, 8, 12, 18 & 24.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jul 2027, 22 months after the start.

Of 45 phase 2 interventional studies under Vitiligo, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 26. This study's planned 22 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion May 2026 → Jul 2027 and completion Jun 2026 → Jul 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2025
First posted
Aug 5, 2025
StartActual
Aug 20, 2025
Primary completionEst.
Jul 1, 2027was May 2026
CompletionEst.
Jul 1, 2027was Jun 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 20, 2026
Start date
Aug 1, 2025→Aug 20, 2025 (actual)
Nov 20, 2026
Primary completion
May 15, 2026→Jul 1, 2027
Nov 20, 2026
Study completion
Jun 15, 2026→Jul 1, 2027
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Recruiting→Active, not recruiting
    Start date Aug 1, 2025→Aug 20, 2025 (now actual)
    Primary completion May 15, 2026→Jul 1, 2027
    Study completion Jun 15, 2026→Jul 1, 2027
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07105254
Lead sponsor
Derm Texas, PLLC
Responsible party
Sponsor
First posted
Aug 5, 2025
Start date
Aug 20, 2025
Primary completion
Jul 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Nov 20, 2026

Study contacts

Kelly Warren, MD
principal investigator · Derm Texas, PLLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion